SCHEMBL15833763

SCHEMBL15833763

Oc1ccc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 6/20 0.84
CLK1 P49759 2/20 0.79
DYRK2 Q92630 2/20 0.79
DYRK1B Q9Y463 2/20 0.79
CLK2 P49760 2/20 0.79
CLK4 Q9HAZ1 2/20 0.79
AXL P30530 5/20 0.74
CDK8 P49336 1/20 0.74
TNIK Q9UKE5 1/20 0.74
SGK1 O00141 1/20 0.67
CAMKK2 Q96RR4 1/20 0.67
NTRK1 P04629 2/20 0.66
CDC7 O00311 1/20 0.64
PLK4 O00444 1/20 0.64
CHEK1 O14757 1/20 0.64
AURKA O14965 1/20 0.64
MAPK13 O15264 1/20 0.64
PDPK1 O15530 1/20 0.64
DYRK3 O43781 1/20 0.64
ROCK2 O75116 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15833810 0.92 DYRK1A (1.00) DYRK1ACLK1DYRK2DYRK1BCLK2
SCHEMBL15833808 0.90 DYRK1A (1.00) DYRK1ACLK1DYRK2DYRK1BCLK2
SCHEMBL15833806 0.88 DYRK1A (1.00) DYRK1ACLK1DYRK2DYRK1BCLK2
SCHEMBL17211633 0.88 DYRK1A (0.82) DYRK1ACLK1DYRK2DYRK1BCLK2
SCHEMBL15833892 0.86 DYRK1A (0.89) DYRK1ACLK1DYRK2DYRK1BAXL
SCHEMBL3771174 0.86 DYRK1A (0.89) DYRK1ACLK1DYRK2DYRK1BAXL
SCHEMBL8941685 0.85 AXL (1.00) DYRK1ACLK1DYRK2DYRK1BCLK2
SCHEMBL1516702 0.85 AXL (0.76) DYRK1ACLK1DYRK2DYRK1BCLK2
SCHEMBL15833800 0.83 AXL (0.73) DYRK1ACLK1DYRK2DYRK1BCLK2
SCHEMBL15833807 0.83 DYRK1A (1.00) DYRK1ACLK1DYRK2DYRK1BCLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447093-B2 3,5-diarylazaindoles as DYRK1A protein inhibitors for the treatment of cognitive deficiencies associated with Down's syndrome and with Alzheimer's disease CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2016-09-20 US disclosed
US-9447093-B2 3,5-diarylazaindoles as DYRK1A protein inhibitors for the treatment of cognitive deficiencies associated with Down's syndrome and with Alzheimer's disease CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2016-09-20 US disclosed
US-9447093-B2 3,5-diarylazaindoles as DYRK1A protein inhibitors for the treatment of cognitive deficiencies associated with Down's syndrome and with Alzheimer's disease CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2016-09-20 US disclosed
US-20150307492-A1 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-10-29 US disclosed
US-20150307492-A1 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-10-29 US disclosed
US-20150307492-A1 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-10-29 US disclosed
WO-2014096093-A1 3,5-DIARYLAZAINDOLES AS DYRK1A PROTEIN INHIBITORS FOR THE TREATMENT OF COGNITIVE DEFICIENCES ASSOCIATED WITH DOWN'S SYNDROME AND WITH ALZHEIMER'S DISEASE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2014-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307492-A1 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease DYRK1A, DYRK3, DYRK2 DYRK1A 1/4885CLK1 87/4885DYRK2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.